Navidea Biopharmaceuticals, Inc. (NAVB): Price and Financial Metrics

Navidea Biopharmaceuticals, Inc. (NAVB): $0.29

0.00 (0.55%)

POWR Rating

Component Grades













Add NAVB to Watchlist
Sign Up

Industry: Biotech



in industry

NAVB Stock Summary

  • NAVB has a higher market value than only 2.67% of US stocks; more precisely, its current market capitalization is $9,385,665.
  • With a price/sales ratio of 81.34, NAVIDEA BIOPHARMACEUTICALS INC has a higher such ratio than 97.19% of stocks in our set.
  • As for revenue growth, note that NAVB's revenue has grown -83.53% over the past 12 months; that beats the revenue growth of merely 1.67% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to NAVIDEA BIOPHARMACEUTICALS INC, a group of peers worth examining would be HSTO, BJDX, NURO, AIM, and GEOS.
  • NAVB's SEC filings can be seen here. And to visit NAVIDEA BIOPHARMACEUTICALS INC's official web site, go to

NAVB Valuation Summary

  • NAVB's price/sales ratio is 80.9; this is 1486.27% higher than that of the median Healthcare stock.
  • Over the past 243 months, NAVB's price/sales ratio has gone up 80.

Below are key valuation metrics over time for NAVB.

Stock Date P/S P/B P/E EV/EBIT
NAVB 2023-01-30 80.9 -2.0 -0.5 -0.4
NAVB 2023-01-27 76.5 -1.9 -0.5 -0.4
NAVB 2023-01-26 79.1 -1.9 -0.5 -0.4
NAVB 2023-01-25 74.8 -1.8 -0.5 -0.4
NAVB 2023-01-24 76.5 -1.9 -0.5 -0.4
NAVB 2023-01-23 73.9 -1.8 -0.5 -0.4

NAVB Growth Metrics

    Its year over year net cashflow from operations growth rate is now at 5.57%.
  • Its 4 year price growth rate is now at -88.89%.
  • Its 2 year revenue growth rate is now at -47.21%.
NAVB's revenue has moved down $542,436 over the prior 33 months.

The table below shows NAVB's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 0.11539 -9.281866 -17.38457
2022-06-30 0.204256 -9.436224 -12.0767
2022-03-31 0.407776 -9.711727 -11.75128
2021-12-31 0.531513 -10.21815 -11.73093
2021-09-30 0.700416 -10.04659 -11.08244
2021-06-30 0.872423 -10.66532 -11.9495

NAVB Stock Price Chart Interactive Chart >

Price chart for NAVB

NAVB Price/Volume Stats

Current price $0.29 52-week high $1.24
Prev. close $0.29 52-week low $0.16
Day low $0.28 Volume 113,800
Day high $0.31 Avg. volume 225,860
50-day MA $0.26 Dividend yield N/A
200-day MA $0.48 Market Cap 9.32M

Navidea Biopharmaceuticals, Inc. (NAVB) Company Bio

Navidea Biopharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of precision radiopharmaceutical diagnostics for diseases such as cancer.

NAVB Latest News Stream

Event/Time News Detail
Loading, please wait...

NAVB Latest Social Stream

Loading social stream, please wait...

View Full NAVB Social Stream

Latest NAVB News From Around the Web

Below are the latest news stories about NAVIDEA BIOPHARMACEUTICALS INC that investors may wish to consider to help them evaluate NAVB as an investment opportunity.

The Navidea Biopharmaceuticals Inc. (NAVB) had a good session last reading, didn’t it?

Navidea Biopharmaceuticals Inc. (AMEX:NAVB) marked $0.27 per share on Tuesday, up from a previous closing price of $0.21. While Navidea Biopharmaceuticals Inc. has overperformed by 28.57%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NAVB fell by -73.00%, with highs and lows ranging from $1.27 to […]

US Post News | January 4, 2023

Navidea stock soars ~25% on upcoming US patent linked to cancer drug pipeline

Navidea Biopharmaceuticals (NAVB) stock rose ~25% after the company said it received a notice of allowance from the U.S

Seeking Alpha | January 3, 2023

Navidea Biopharmaceuticals Announces the Notice of Allowance for U.S. Patent Application for Key Component of the Company’s Cancer Immunotherapy Pipeline

DUBLIN, Ohio, January 03, 2023--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application titled, "Compositions And Methods For Altering Macrophage Phenotype (US Application #16/832,620)." Broadly, this patent covers the ability of Navidea’s const

Yahoo | January 3, 2023

Navidea Biopharmaceuticals, Inc. (AMEX:NAVB) Q3 2022 Earnings Call Transcript

Navidea Biopharmaceuticals, Inc. (AMEX:NAVB) Q3 2022 Earnings Call Transcript November 15, 2022 Operator: Greetings and welcome to the Navidea Biopharmaceuticals’ Quarter Three Earnings Call and Business Update. And as a reminder this conference call is being recorded. It is now my pleasure to introduce Dr. Michael Rosol, Chief Medical Officer. Thank you, Michael. You may […]

Yahoo | December 28, 2022

Navidea Biopharmaceuticals Files Appeal in CRG Case

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that on November 29, 2022, Navidea and its majority-owned subsidiary Macrophage Therapeutics, Inc. filed an appeal of the judgment by the District Court of Harris County, Texas in Case No. 2018-24442-151; Capital Royalty Partners II, L.P. et al. v. Navidea Biopharmaceu

Business Wire | November 30, 2022

Read More 'NAVB' Stories Here

NAVB Price Returns

1-mo N/A
3-mo 22.16%
6-mo -49.17%
1-year -69.98%
3-year -75.83%
5-year -95.97%
YTD 38.10%
2022 -79.00%
2021 -53.49%
2020 70.63%
2019 -37.00%
2018 -72.22%

Continue Researching NAVB

Here are a few links from around the web to help you further your research on Navidea Biopharmaceuticals Inc's stock as an investment opportunity:

Navidea Biopharmaceuticals Inc (NAVB) Stock Price | Nasdaq
Navidea Biopharmaceuticals Inc (NAVB) Stock Quote, History and News - Yahoo Finance
Navidea Biopharmaceuticals Inc (NAVB) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7292 seconds.